Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

RheumaView · Chapter 17 · Patient guide

Remission, tapering and stopping treatment in r-axSpA

What happens when things are going well?

After months or years of treatment, a very different question can arise:

“I feel well. Do I still need this medication?”

Olga Goodman, MD · A RheumaView publication

Sources checked: October 1, 2026

This is an important question.

When radiographic axial spondyloarthritis (r-axSpA) becomes well controlled, the goal is not automatically to continue every treatment forever at exactly the same dose.

But it is also not safe to assume:

“I feel better, therefore the disease is gone.”

Current evidence makes an important distinction between:

remission

sustained remission

tapering

and

stopping treatment completely.

They are not the same thing.

The central principle is:

When axSpA is doing well, treatment can sometimes be reduced carefully—but complete withdrawal carries a substantially greater risk of flare.

First: what does “remission” mean?

In everyday language, remission means:

“The disease seems quiet.”

In axial SpA, the term can be defined in several ways.

Doctors may use:

  • inactive disease;
  • low disease activity;
  • clinical remission;
  • sustained remission.

These terms overlap, but they are not completely interchangeable.

ASDAS inactive disease

The Axial Spondyloarthritis Disease Activity Score — ASDAS is one validated way to follow activity. ASAS–EULAR favors ASDAS; the 2026 ACR/SAA/SPARTAN summary supports regular use of ASDAS or BASDAI. The main explanation of these measures is in measuring activity. [S01, S02, S05]

An ASDAS below 1.3 is called:

inactive disease.

An ASDAS from 1.3 to below 2.1 is:

low disease activity.

These are useful treatment states.

But even ASDAS inactive disease does not mean:

  • the diagnosis disappeared;
  • previous structural damage reversed;
  • the immune disease can never become active again;
  • or medication can automatically be stopped.

It describes the current disease state.

Remission is not the same as cure

This distinction is fundamental.

r-axSpA is a chronic immune-mediated disease.

Treatment may suppress the disease so effectively that:

  • symptoms become minimal;
  • CRP normalizes;
  • ASDAS becomes inactive;
  • function returns;
  • inflammatory manifestations disappear.

That is an excellent outcome.

But:

Successful suppression of disease is not proof that the tendency toward disease has disappeared.

Sometimes the reason the disease is quiet is precisely because the treatment is working.

Check your understanding 1

A patient has felt excellent for eight months while taking a biologic.

CRP is normal and ASDAS is in the inactive range.

Which conclusion is most accurate?

A “The diagnosis must have been wrong.”

B “The disease is cured, so treatment should stop.”

C “The disease is very well controlled; whether treatment can be reduced is now a reasonable discussion.”

Show answer and explanation

Answer: C.

Good disease control creates an opportunity for shared decision-making.

It does not automatically create an indication to stop treatment.

What does “sustained remission” mean?

One excellent visit is not the same as sustained remission.

A patient may temporarily feel better because:

  • disease activity fluctuates;
  • treatment was recently intensified;
  • symptoms happen to be lower that week;
  • another factor has changed.

Before reducing treatment, clinicians generally want evidence that good control has persisted.

There is no universally accepted single definition of sustained remission in axSpA.

However, current international guidance commonly uses a practical concept such as:

inactive or low disease activity maintained for at least about six months

before considering tapering. ASAS–EULAR describes the six-month benchmark as a practical, arbitrary minimum; it is not an eligibility test. [S02]

That six-month period is not a biological law.

It is a practical minimum used to avoid reducing treatment immediately after the first good response.

Why wait?

Imagine:

Visit 1

Treatment has just started working.

Visit 2

Symptoms remain excellent.

Visit 3

Disease remains consistently controlled.

The confidence that remission is stable increases over time.

Reducing treatment after one unusually good week carries more uncertainty than reducing it after sustained stable control.

What is tapering?

Tapering means reducing treatment exposure without immediately stopping treatment completely.

Depending on the medication, this may involve:

  • increasing the interval between doses;
  • reducing the dose;
  • or another planned reduction strategy.

For biologics in axSpA, research has most commonly studied spacing doses farther apart.

The exact approach depends on the drug.

Do not create a tapering schedule yourself.

Some dose-spacing approaches are outside the medication’s formally approved dosing schedule even though they are used clinically in carefully selected circumstances.

A taper, a temporary interruption and a withdrawal

A planned taper aims to preserve control with less exposure. A temporary interruption addresses another problem, such as an infection or operation, and needs separate instructions for restarting. Complete withdrawal ends ongoing treatment.

Ask which change is actually being proposed. “Take it less often” is not a clear prescription. A different injection schedule can preserve the same total dose, so fewer injection days do not necessarily mean less medicine.

Tapering is not the same as skipping medication randomly

There is a major difference between:

Planned tapering

A deliberate strategy agreed upon with the clinician, with:

  • stable disease first;
  • a defined change;
  • monitoring;
  • and a plan if symptoms return.

and:

Unplanned under-treatment

Repeatedly delaying or skipping doses because:

  • you feel well;
  • you forgot;
  • access is difficult;
  • you want to “test” whether you still need treatment.

The second approach makes it much harder to understand what the medication is doing.

Why might tapering be considered?

There are several reasonable motivations.

A patient may want to reduce:

  • medication burden;
  • injections;
  • inconvenience;
  • treatment exposure;
  • or cost.

There may also be a desire to use the lowest treatment exposure that maintains reliable control.

Tapering may be especially reasonable to discuss when:

  • disease has been consistently inactive or low;
  • there have been no recent flares;
  • extra-musculoskeletal disease is also controlled;
  • treatment is being taken reliably;
  • and the patient understands the possibility that symptoms may return.

What does the evidence show?

Trials have compared three broad strategies in people whose axSpA was well controlled:

continue standard treatment

reduce treatment

stop treatment

The general pattern is important.

Continuing treatment

Maintains control for many people. Continuing and reducing treatment have sometimes produced similar results in selected patients in sustained remission.

Tapering

Can maintain good control in many patients and, in TNF-inhibitor studies, dose reduction was not inferior to full-dose treatment for many patients in sustained remission.

Complete withdrawal

Produces substantially more flares.

For this reason, the 2025 British Society for Rheumatology guideline recommends considering tapering in sustained remission but recommends against complete withdrawal as the routine strategy.

ASAS-EULAR similarly supports cautious bDMARD tapering in sustained remission rather than abrupt discontinuation.

Check your understanding 2

A patient has been in sustained remission.

Which approach has the greatest risk of flare?

A Continuing standard treatment.

B Carefully tapering treatment.

C Stopping treatment completely.

Show answer and explanation

Answer: C.

The difference between reducing and stopping is clinically important.

How high is the flare risk after stopping?

The risk depends on the medicine, the people studied and the definition of flare.

In C-OPTIMISE, people with early radiographic or non-radiographic axSpA first received certolizumab. Only those who achieved sustained remission entered the randomized maintenance comparison. During the next 48 weeks, 83.7% remained flare-free with the full maintenance regimen, 79.0% with the reduced regimen and 20.2% after withdrawal. [S04]

These are results for selected early-disease responders receiving one medicine, not your personal odds. They do not prove equivalent reduction strategies for every biologic or JAK inhibitor. They do show why stopping and a monitored reduction should not be treated as the same experiment.

If I flare, can’t I simply restart?

Often disease control can be regained after restarting effective treatment.

But not always immediately.

And not everyone in withdrawal studies regained the same level of control within the study period.

That matters.

Stopping treatment is not always a completely reversible experiment.

Other practical problems can also appear:

  • insurance may require authorization again;
  • the original treatment may no longer be immediately available;
  • symptoms may interfere with work or sleep while control is being regained;
  • uveitis, psoriasis or IBD may also return.

So the decision should consider more than the possibility of back pain returning.

Remission belongs to the whole disease—not just the spine

Before tapering, ask whether all important manifestations are controlled.

For example:

Axial disease

No significant inflammatory activity?

Eyes

No recurrent uveitis?

Skin

Psoriasis controlled?

Bowel

IBD controlled?

Peripheral joints and entheses

Stable?

A patient may say:

“My back has been perfect for a year.”

But if uveitis has flared three times, the overall inflammatory disease is not necessarily in the state that makes treatment reduction attractive.

Check your understanding 3

The spine is quiet and ASDAS is low.

But Crohn disease remains active.

Is this straightforward sustained remission?

Show answer and explanation

No.

A systemic therapy may be serving more than one disease manifestation.

The decision to reduce it should consider the whole phenotype and may require coordination with gastroenterology or another specialist.

Which medications have the best evidence for tapering?

Most direct tapering evidence in axSpA has historically come from TNF inhibitors.

There is less evidence for tapering other targeted pathways.

ASAS-EULAR 2022 therefore specifically based its tapering recommendation largely on TNFi evidence.

The newer BSR 2025 guideline frames tapering more broadly for targeted therapies but also notes that the randomized tapering trials were predominantly TNFi studies.

This is important because:

Evidence for reducing one treatment should not automatically be assumed to apply identically to every medication.

Why might two rheumatologists give different answers?

Guidelines and individual circumstances both matter. For adults with inactive axSpA taking a biologic or targeted synthetic disease-modifying medicine, the 2026 ACR/SAA/SPARTAN summary conditionally favors reducing the dose or dosing frequency and strongly recommends against withdrawing that treatment without tapering. This is the official summary, not a claim that a full 2026 journal guideline has been published. [S01]

ASAS–EULAR and the 2025 BSR guideline also support considering tapering after sustained control. This does not mean everyone in remission should reduce treatment. A clinician may reasonably recommend continuing because of recurrent eye or bowel disease, previous rapid relapse, uncertain control or the consequences of another flare. [S02, S03]

Ask what makes reduction more or less suitable for your situation. The old description of a general American-versus-European divide on tapering no longer reflects the 2026 summary.

What factors might make tapering more attractive?

There is no perfect prediction model.

But the conversation may be more favorable when:

  • remission has been sustained;
  • CRP is normal when CRP is a useful marker for that patient;
  • ASDAS is consistently low or inactive;
  • there have been no recent inflammatory flares;
  • extra-musculoskeletal disease is quiet;
  • there is no evidence suggesting significant residual inflammatory activity;
  • the patient has reliable follow-up;
  • and there is a clear plan if disease returns.

What might make clinicians more cautious?

Examples include:

  • only recently achieving control;
  • frequent previous flares;
  • residual high disease activity;
  • recurrent uveitis;
  • active psoriasis or IBD;
  • previous rapid relapse when doses were delayed;
  • difficult-to-control disease before remission;
  • high consequences if a flare occurs;
  • or uncertainty about whether disease is genuinely inactive.

The treatment decision depends on the cost of losing control, not simply the desire to use less medication.

“My MRI is normal. Does that mean I can stop?”

No.

MRI can contribute useful information in selected situations.

But current guidance does not recommend routinely obtaining MRI simply to prove inactivity in every clinically stable patient.

And a normal MRI does not guarantee that disease will remain quiet without treatment.

The decision is based on the whole longitudinal picture.

“My CRP is normal. Can I taper?”

Possibly—but CRP is only one factor.

A normal CRP is more informative in someone whose CRP previously rose when disease was active.

It is less informative in someone whose CRP has always remained normal.

Ask:

“Does CRP actually track my disease?”

rather than:

“Is the number normal?”

“I have no pain. Does that mean remission?”

Not necessarily.

No pain is excellent.

But pain and inflammation are not perfectly interchangeable.

A clinician may still consider:

  • stiffness;
  • ASDAS;
  • CRP;
  • peripheral disease;
  • eye/skin/bowel manifestations;
  • and the overall clinical course.

Conversely, a patient may have excellent inflammatory control but still experience some structural or mechanical pain.

That does not automatically mean remission has failed.

How should tapering be done?

There is no universal schedule.

The principle is:

one deliberate step at a time.

A practical approach may be:

  1. Confirm stable disease control.
  2. Agree on the treatment-reduction goal.
  3. Make one planned reduction.
  4. Continue monitoring.
  5. Reassess before reducing further.
  6. Reverse course if meaningful inflammatory disease returns.

ASAS-EULAR specifically emphasizes gradual tapering with reassessment before proceeding to another reduction step.

Check your understanding 4

Which tapering strategy makes more sense?

A “I feel good, so I will skip the next three injections and see what happens.”

B “My disease has been consistently controlled. My rheumatologist and I will lengthen the dosing interval, reassess, and decide whether to reduce further.”

Show answer and explanation

Answer: B.

Tapering is a monitored treatment strategy.

It is not random medication omission.

What should be monitored during tapering?

You do not need constant laboratory testing or daily questionnaires.

Useful monitoring may include:

Familiar inflammatory symptoms

  • morning stiffness;
  • nighttime inflammatory pain;
  • buttock/spinal symptoms.

Function

Is exercise, work or daily activity becoming more difficult?

Disease activity

ASDAS when routinely used.

CRP

When CRP is informative for that individual.

Extra-musculoskeletal disease

  • eye inflammation;
  • psoriasis;
  • bowel disease.

Peripheral disease

  • swollen joints;
  • enthesitis.

The goal is to identify a real return of inflammatory disease before a prolonged flare develops.

One bad day is not automatically a flare

Pain fluctuates.

During tapering, patients may become understandably vigilant and interpret every symptom as disease recurrence.

A temporary increase in pain may result from:

  • unusual physical activity;
  • poor sleep;
  • a mechanical strain;
  • viral illness;
  • stress;
  • or another common cause.

The decision to reverse tapering should generally be based on the pattern, not one isolated uncomfortable day.

But do not ignore a convincing return of inflammatory symptoms

Examples may include:

  • progressive morning stiffness;
  • return of characteristic nighttime symptoms;
  • increasing inflammatory buttock/spinal pain;
  • rising disease-activity score;
  • objective inflammatory findings;
  • recurrent uveitis or other manifestations.

The treating clinician may recommend returning to the previous effective regimen.

What if the disease flares during tapering?

A flare does not mean tapering was a mistake.

It provides information:

The reduced treatment exposure may not be enough to maintain control.

Often the strategy is to return to the last effective dose or interval.

The exact response depends on:

  • severity;
  • manifestation involved;
  • current medication;
  • and individual circumstances.

What if I want to stop completely anyway?

Patients ultimately make their own treatment decisions.

A person may decide that complete withdrawal is worth trying despite the higher flare risk.

That decision should ideally be made with full information.

Important questions include:

  • How likely is relapse?
  • What happened during previous interruptions?
  • What manifestations could return?
  • How quickly can I obtain clinical review?
  • Can the previous treatment be restarted promptly?
  • What should I do if uveitis or IBD returns?
  • How will we define a flare?
  • What are the consequences if disease control is not quickly regained?

Current BSR guidance explicitly recognizes that some informed patients may still choose withdrawal and recommends that they have access to timely clinical review if they do.

Stopping because of side effects is a different problem

This article is about reducing treatment because disease is doing well.

That is different from needing to stop because of:

  • serious infection;
  • significant adverse effect;
  • pregnancy-related treatment considerations;
  • surgery;
  • laboratory toxicity;
  • malignancy;
  • or another safety issue.

In those situations the decision may need to happen quickly and may involve switching rather than tapering.

Do not use a remission-taper plan to manage a safety problem.

What about NSAIDs?

A person whose targeted treatment has controlled inflammatory disease may also be able to reduce other medications.

For example, continuous NSAID use may no longer be necessary if symptoms are controlled.

Because NSAIDs carry gastrointestinal, renal, blood-pressure and cardiovascular risks, avoiding unnecessary long-term exposure can be valuable.

But medication changes should be considered individually.

The goal is not to reduce everything at once.

Why change one thing at a time?

Suppose a patient simultaneously:

  • spaces the biologic;
  • stops NSAIDs;
  • doubles exercise;
  • changes diet;
  • and stops another pain medication.

Then symptoms return.

What caused the change?

It becomes difficult to know.

Changing one major treatment variable at a time makes the response easier to interpret.

Is tapering mainly about saving money?

No.

Cost can be a legitimate practical factor.

But the clinical reason for tapering is broader:

Can reliable disease control be maintained with less treatment exposure?

Potential advantages may include:

  • fewer injections;
  • lower medication burden;
  • convenience;
  • and possibly lower cost.

However, a lower dose that leads to recurrent flares is not necessarily a better treatment strategy.

Does tapering reduce infection risk?

Possibly, but this should not be assumed to be dramatic.

Most tapering trials were designed primarily to determine whether disease control could be maintained, not to prove large differences in rare safety outcomes.

BSR notes that trials did not show a clear difference in adverse events between reduced and standard TNFi dosing, but they were not powered to make definitive safety comparisons.

So tapering should not be marketed as a guaranteed safety intervention.

What about structural progression?

This remains an important unanswered area.

Persistent inflammatory disease activity is associated with greater structural progression at the population level.

But we have less certainty about the long-term effect of different tapering strategies on structural progression.

ASAS-EULAR specifically identifies this as an area requiring further research.

That is another reason tapering should preserve disease control rather than simply minimize medication.

Check your understanding 5: what is the actual goal?

Which is the best tapering goal?

A Use as little medication as possible regardless of symptoms.

B Reach zero medication as quickly as possible.

C Find the lowest treatment exposure that maintains reliable disease control, if reduction is appropriate.

Show answer and explanation

Best answer: C.

Tapering is successful only if the disease remains acceptably controlled.

A realistic example

A patient has:

  • ASDAS inactive disease for nine months;
  • normal CRP that historically tracks disease activity;
  • no uveitis;
  • no active psoriasis or IBD;
  • excellent function;
  • no recent flares.

Reasonable question:

“Could we cautiously increase the interval between doses?”

Yes.

That is exactly the kind of situation in which modern guidelines support discussing tapering.

Another example

A patient says:

“My back feels great, so I want to stop.”

But during the last six months there have been:

  • two episodes of uveitis;
  • active Crohn disease;
  • and increasing enthesis symptoms.

Is this uncomplicated sustained remission?

No.

Spinal symptoms are only one part of the disease.

And another

A patient is doing well but whenever a dose is delayed by two weeks because of insurance problems:

  • morning stiffness returns;
  • night pain returns;
  • and symptoms improve again after regular therapy resumes.

What does that suggest?

The medication may still be actively suppressing the disease.

That history should be part of the tapering discussion.

A practical tapering conversation

Before leaving the appointment, write down these points together:

Part of the plan What to record
Exact change Medicine, dose, interval, dates and first day of the new schedule. Ask whether the schedule is on-label or off-label.
What stays unchanged Other medicines and the agreed activity or rehabilitation plan.
Monitoring The few symptoms, functional changes and tests to follow; whether CRP usually tracks your disease.
Review When and by whom; how to contact the team sooner.
Recurrence What should prompt contact, what is already covered by your prescription and what needs a new decision. Include eye, skin and bowel symptoms.

This is an appointment aid, not a dosing algorithm. Do not copy another person’s schedule. Ask how the team will check that control has returned if the plan has to be changed. A previous response should be reassessed, not promised.

The key message

When r-axSpA becomes quiet, there are three different choices:

continue

taper

or:

stop.

They do not carry the same probability of maintaining disease control.

Current evidence supports a cautious middle path for selected patients:

After sustained remission, gradual tapering can be considered through shared decision-making.

Complete withdrawal is much more likely to result in flare and is not the routine recommended strategy.

The objective is not:

“How quickly can I get off treatment?”

It is:

“What is the least treatment exposure that can reliably preserve the disease control, function and quality of life we worked to achieve?”

Sometimes the answer is a lower treatment exposure.

Sometimes the answer is the current regimen.

Both can represent successful care.

Selected evidence sources

S01. ACR/SAA/SPARTAN. 2026 axial spondyloarthritis guideline summary, posted June 24, 2026. Official summary.

S02. Ramiro S, et al. ASAS–EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19–34. doi:10.1136/ard-2022-223296.

S03. Zhao SS, et al. The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs. Rheumatology. 2025. doi:10.1093/rheumatology/keaf089.

S04. Landewé RBM, et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis. 2020;79:920–928. doi:10.1136/annrheumdis-2019-216839.

S05. ASAS. ASDAS calculator and calculation guidance.

Sources checked: October 1, 2026. The examples and checkpoints are fictional educational scenarios.

Educational information only. Do not reduce, delay, space or discontinue prescription therapy based on this article. Agree a monitoring and recurrence plan with your treating clinician.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Spondyloarthritis